Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents

Clinical Infectious Diseases

Volumn 63, Issue 5, 2016, Pages 651-653

  Van Hise, Nicholas W ^a   Bryant, Alex M ^b   Hennessey, Erin K ^b,c   Crannage, Andrew J ^b,c   Khoury, Jad A ^b   Manian, Farrin A ^d  

^a Edward Elmhurst Healthcare   (United States)

^b MERCY HOSPITAL   (United States)

^c Medication Management Program   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antimicrobial agents; Clostridium difficile; prophylaxis; vancomycin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK REDUCTION; SYSTEMIC THERAPY; VULNERABLE POPULATION; CLOSTRIDIUM INFECTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PEPTOCLOSTRIDIUM DIFFICILE; PREGNANCY; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84995378142     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw401     Document Type: Conference Paper

References (9)

1. Dubberke ER, Butler AM, Reske KA. Attributable outcomes in endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008; 14:1031-6.
2. Miller MA, Hyland MA. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control and Hosp Epidemiol 2002; 23:137-40.
3. Hensgens M, Goorhuis A, Dekkers O, Kuijper E. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012; 67:742-8.
4. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double blinded trial. Clin Infect Dis 1997; 24:324-33.
5. Luo RF, Banaei N. Is repeat PCT needed for diagnosis of Clostridium difficile infection? J Clin Microbiol 2010; 48:3738-41.
6. Peterson LR, Robicsek A. Does my patient have Clostridium difficile infection? Ann Intern Med 2009; 151:176-9.
7. Deshpande A, Pasupuleti V, Rolston DDK, et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a meta-analysis. Clin Infect Dis 2011; 53:e81-90.
8. Al-Nassir WA, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile associated disease. Antimicrob Agents Chemother 2008; 52:2403-6.
9. Gonzales M, Pepin J, Frost EH, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 2010; 10:363.